Immunovia AB
1YR
Company Profile
Business description
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
Contact
Scheelevagen 8
Medicon Village
Lund223 63
SWET: +46 462756000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Higher fair value for undervalued wide moat share
Investors are overly concerned with upcoming capital expenditures.
stocks
Fears of deteriorating loan quality sends bank share plummeting
We maintain our fair value estimate despite unfavourable economic conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,026.90 | 46.30 | 0.52% |
| CAC 40 | 8,384.87 | 46.74 | -0.55% |
| DAX 40 | 24,671.22 | 323.61 | -1.29% |
| Dow JONES (US) | 51,876.11 | 44.51 | -0.09% |
| FTSE 100 | 10,508.02 | 21.87 | -0.21% |
| HKSE | 23,096.48 | 424.62 | 1.87% |
| NASDAQ | 25,297.62 | 60.99 | -0.24% |
| Nikkei 225 | 69,382.07 | 21.19 | 0.03% |
| NZX 50 Index | 13,545.56 | 50.32 | 0.37% |
| S&P 500 | 7,354.02 | 3.47 | -0.05% |
| S&P/ASX 200 | 8,823.40 | 46.50 | 0.53% |
| SSE Composite Index | 4,048.80 | 21.53 | 0.53% |